Analysis of nuclear DNA and morphometry, and proliferating cell nuclear antigen in primary and metastatic malignant melanoma

Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery

Volumn 31, Issue 2, 1997, Pages 109-118

  Björnhagen, Viveca ^a   Lindholm, Johan ^a   Auer, Gert ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DNA; Heterogeneity; Melanoma; Metastasis; Morphometry; PCNA

Indexed keywords

CELL NUCLEUS DNA; CYCLINE;

ADULT; AGED; ARTICLE; BRAIN; CELL STRUCTURE; CLINICAL ARTICLE; DNA CONTENT; FEMALE; HUMAN; LYMPH NODE; MALE; MELANOMA; REGRESSION ANALYSIS; SKIN;

EID: 0030973149     PISSN: 02844311     EISSN: None     Source Type: Journal    
DOI: 10.3109/02844319709085477     Document Type: Article

References (48)

1. Armitage P. Statistical methods in medical research. Oxford Blackwell Scientific Publications, 1971: 189-268.
2. Auer GU, Caspersson TO, Wallgren A. DNA content and survival in mammary carcinoma. Anal Quant Cytol 1980; 2: 161-165.
3. Auer GU, Arrhenius E, Granberg PO, Fox CH. Comparison of DNA distributions in primary human breast cancers and their metastases. Eur J Cancer 1980; 16: 273-278.
4. Baak JPA, Tan G. The adjuvant prognostic value of nuclear morphometry in stage I malignant melanoma of the skin. A multivarate analysis. Anal Quant Cytol Histol 1986; 8: 241-244.
5. Balaban G, Herlyn M, Clark WH, Nowell PC. Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet 1986; 19: 113-122.
6. Björnhagen V, Månsson-Brahme E, Lindholm J, Mattsson A, Auer G. Morphometric, DNA and PCNA analyses in thin malignant melanomas. Med Oncol Tumor Pharmacother 1993; 10: 87-94.
7. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987; 326: 515-517.
8. Bröcker E-B, Suter L, Brüggen J, Ruiter DJ, Macher E, Sorg C. Phenotypic dynamics of tumor progression in human malignant melanoma, Int J Cancer 1985; 36: 29-35.
9. Bäckdahl M, Auer G, Forsslund G, et al. Prognostic value of nuclear DNA-content in follicular thyroid tumors. Acta Chir Scand 1986; 152: 1-7.
10. Bäckdahl M, Cohn K, Auer G, et al. Comparison of nuclear DNA content in primary and metastatic papillary thyroid carcinoma. Cancer Res 1985; 45: 2890-2894.
11. Cho KR, Vogelstein B. Suppressor gene alterations in the colorectal adenomacarcinoma sequence. J Cell Biochem Suppl 1992; 16G: 137-141.
12. Cillo C, Mach J-P, Schreyer M, Carrel S. Antigenic heterogeneity of clones and subclones from human melanoma cell lines demonstrated by a panel of monoclonal antibodies and flow microfluorometry analysis. Int J Cancer 1984; 34: 11-20.
13. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. Ann Surg 1991; 214: 627-636.
14. Costa A, Silvestrini R, Grignolio E, Clemente C, Attili A, Testori A. Cell kinetics as a prognostic tool in patients with metastatic malignant melanoma of the skin. Cancer 1987; 60: 2797-2800.
15. Cox DR. Regression models and life-tables (with discussion). Journal of the Royal Statistical Society 1972; 34: 187-220.
16. Diebold J, Lai MD, Liohrs U. Analysis of proliferative activity in colorectal mucosa by immunohistochemical detection of proliferating cell nuclear antigen (PCNA). Methodological aspects and application to routine diagnostic material. Virchows Arch B Cell Pathol 1992; 62: 283-289.
17. Forsslund G, Esposti P, Nilsson B, Zetterberg A. The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 1992; 69: 1432-1439.
18. Gamel JW, McLean IW. Computerized histopathologic assessment of malignant potential. A practical method for predicting survival following enucleation for uveal melanoma. Cancer 1983; 5: 1032-1038.
19. Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 1989; 134: 733-739.
20. Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285-294.
21. Helander KG, Tribukait B. Modal DNA values of normal and malignant urothelial cells of the bladder in relation to nuclear size. Anal Quant Cytol Histol 1988; 10: 127-133.
22. Heppner HG. Tumor heterogeneity. Cancer Res 1984; 44: 2259-2265.
23. Herlyn M, Balaban G, Bennicelli J, et al. Primary melanoma cells from the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 1985; 74: 283-289.
24. Kamel OW, LeBrun DP, Davis RE, Berry GJ, Warnke RA. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/cyclin 19A2. Correlation with Ki-67 labelling. Am J Pathol 1991; 138: 1471-1477.
25. Kamino H, Ratech H. Improved detection of aneuploidy in malignant melanoma using multiparameter flow cytometry for S-100 protein and DNA content. J Invest Dermatol 1989; 93: 392-396.
26. Karlsson M, Boeryd B, Carstensen J, Kågedal B, Ternesten Bratel A, Wingren S. DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease. Br J Cancer 1993; 67: 134-138.
27. Kheir SM, Bines SD, von Roenn JH, Soong S-J, Urist MM, Coon JS. Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg 1988; 207: 455-461.
28. Kreicbergs A, Zetterberg A. Cytophotometric DNA measurements of chondrosarcoma. Methodological aspects of measurements in tissue sections from old paraffin-embedded specimens. Anal Quant Cytol 1980; 2: 84-92.
29. Limon J, Gibas Z, Babinska M, et al. Chromosome changes associated with spontaneous phenotypic variation of transplantable melanoma. Cancer Genet Cytogenet 1987; 25: 123-129.
30. Lindholm C, Hofer PÅ, Jonsson H. Karyometric findings and prognosis of stage I cutaneous malignant melanomas. Acta Oncol 1988; 27: 227-234.
31. Lindholm J, Rubio CA, Kato Y, Hata YI. A morphometric method to discriminate normal from dysplastic/carcinoma in situ squamous epithelium in the human esophagus. Pathol Res Pract 1989; 184: 297-305.
32. Magno WB, Hirschfield L, Bhuiya T, Harrison G, Mir R. Correlation of proliferative index (PCNA reactivity and Ki-67 reactivity) in primary breast carcinoma with hormone status, lymph node status and disease-free survival. Conn Med 1992; 56: 667-669.
33. Moberger B. DNA content and prognosis in endometrial carcinoma. Medical dissertation. Stockholm: Karolinska Institute, 1989.
34. Muhonen T, Pyrhönen S, Laasonen A, et al. Tumour growth rate and DNA flow cytometry parameters as prognostic factors in metastatic melanoma. Br J Cancer 1992; 66: 528-532.
35. Natali PG, Cavaliere R, Bigotti A, et al. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol 1983; 130: 1462-1466.
36. Nicolson GL, Rosenberg N. Diversification and progression of malignant tumors. Bioessays 1988; 6: 204-208.
37. Nomori H, Nakajima T, Noguchi M, Iga R, Shimosato Y. Cytofluorometric analysis of metastases from lung adenocarcinoma with special reference to the difference between hematogenous and lymphatic metastases. Cancer 1991; 67: 2941-2947.
38. van den Ouden D, Tribukait B, Blom JHM, et al. The European organization for research and treatment of cancer genitourinary group. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: Impact on time to progression. J Urol 1993; 150: 400-406.
39. Prelish G, Stillman B. Coordinated leading and legging strand synthesis during SV40 DNA replication in vitro requires PCNA. Cell 1988; 53: 117-126.
40. Rode J, Williams RA, Charlton IG, Dhillon AP, Moss E. Nuclear DNA profiles in primary melanomas and their metastases. Cancer 1991; 67: 2333-2336.
41. Stenkvist B, Bengtsson E, Eriksson O, Jarkrans T, Nordin B, Westman-Naeser S. Correlation between cytometric features and mitotic frequency in human breast carcinoma. Cytometry 1981; 1: 287-291.
42. Sørensen FB, Kristensen IB, Grymer F, Jakobsen A. DNA-index and stereological estimation of nuclear volume in primary and metastatic malignant melanomas: a comparative study with analysis of heterogeneity. APMIS 1990; 98: 61-70.
43. Tan G, Baak JPA. Evaluation of prognostic-characteristics of stage I cutaneous malignant melanoma. Anal Quant Cytol Histol 1984; 6: 147-154.
44. Tuccari G, Rizzo A, Muscarà M, Giuffré G, Barresi G. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinicopathological aspects. Pathologica 1993; 85: 47-55.
45. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319; 523-532.
46. Wass J, Zbroja RA, Young GAR, Vincent PC, Joyce RM, Croaker G. Malignant melanoma: analysis by flow cytometry. Pathology 1985; 17: 475-480.
47. Williams RA, Charlton IG, Rode J. Comparative ploidy studies using cytological and paraffin section preparations. Cytopathology 1991; 2: 29-37.
48. Zeng SQ, Fu YS, Cochran AJ. Nuclear DNA measurement of metastatic melanoma by a computerized digital imaging system. Hum Pathol 1990; 21: 1112-1116.